Skip to main content
Assets
Roche Holding logo
ROP.SIX
Roche Holding
Health Care · Pharmaceuticals

Swiss multinational healthcare company pioneering pharmaceuticals and diagnostics with focus on oncology, immunology, and infectious diseases.

HQ: SwitzerlandListed: Switzerland

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Roche Holding.

Historical AI Opinions

Roche Holding AG (ROG.SIX) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 12 advisor reports and comparisons.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ResearcherAdvisor config deprecated

Investment Expert AI

Investment framework Framework

Model rating

Buy

5-Year Return Est.

+52.3%

Includes 1.82% annual net dividend contribution

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in CHF.197.69262.51327.34392.16456.98Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in CHF.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in CHF. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
CHF 323+3.1%Not Generated this time
CHF 335+7.1%Not Generated this time
CHF 349+11.4%Not Generated this time
CHF 360+15.1%Not Generated this time
CHF 375+19.9%Not Generated this time
CHF 388+24.1%Not Generated this time
CHF 402+28.6%Not Generated this time
CHF 415+32.7%Not Generated this time
CHF 425+35.9%Not Generated this time
CHF 435+39.1%Not Generated this time
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

The most reasonable thesis projects Roche as a steady compounder undergoing a successful but gradual portfolio rotation. Vabysmo continues its strong trajectory, becoming the primary growth driver in the near term. The obesity franchise (CT-388) shows positive Phase 3 data, securing a viable but not dominant market position, contributing meaningfully to revenue by 2028. The Ocrevus franchise proves resilient thanks to the subcutaneous formulation, softening the impact of eventual biosimilars. Diagnostics growth remains steady at mid-single digits. While not all moonshot bets (like Alzheimer's) may succeed fully, the diversity of the pipeline provides a sufficient floor. Valuation gradually expands as the market gains confidence in the post-oncology pivot, justifying the current breakout price level.

2. Scenarios & Signals

2.1. Bull Case

In the bull case, Roche successfully transitions from a legacy oncology powerhouse to a leader in metabolic and neurological diseases. The CT-388 (incretin) program demonstrates best-in-class weight loss efficacy and tolerability in Phase 3 trials, positioning Roche as a formidable third player in the obesity oligopoly alongside Novo Nordisk and Eli Lilly. Concurrently, the 'brain shuttle' asset trontinemab revolutionizes Alzheimer's treatment with superior safety profiles, capturing significant market share. Vabysmo achieves dominance in ophthalmology, exceeding $6 billion in peak sales. The rapid uptake of subcutaneous Ocrevus Zunovo effectively mitigates biosimilar erosion until well into the 2030s. Operational efficiency improves margins, and the Swiss Franc stabilizes, removing currency headwinds. This scenario implies a rerating of Roche's multiple to align with high-growth pharma peers.

2.2. Bear Case

The bear case envisions a 'pipeline cliff' where high-profile late-stage assets fail to deliver commercial viability. If CT-388 fails in Phase 3 due to safety signals or inability to differentiate from entrenched incumbents, the growth premium currently priced in evaporates. Simultaneously, biosimilar erosion for Actemra, Xolair, and eventually Ocrevus accelerates faster than anticipated, dragging down top-line revenue. Vabysmo faces stiff competition from high-dose Eylea, stalling its growth trajectory. The failure of trontinemab in Alzheimer's leaves a gap in the neuroscience portfolio. Persistent strength in the Swiss Franc continues to compress earnings when reported in CHF. Under these conditions, Roche struggles to find replacement revenue, leading to multiple compression and a return to lower valuation bands.

4. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 2,856Thinking Tokens: 2,284Response Tokens: 7,451Total Tokens: 12,591
Researcher modeSearch enabled · not used

This run was configured as Researcher, but no external search activity was recorded. The model proceeded from the supplied context as sufficient, effectively following a Thinker-style workflow.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    Input Prompt Market Equity Balanced System Instruction Driven Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

  2. 02

    Global context in this run

    Not used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Forecast output requested

    Output Json Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.